The widening loss and rapid cash burn (~$15M/quarter) suggest the company may need to raise capital within 12 months. Monitor cash runway and any debt facility draws. The reaffirmed guidance provides a floor but the EPS miss and expense growth are negative signals for a pre-profit company.
Price Chart
Executive Summary
Rapid Micro Biosystems reported Q1 2026 revenue of $8.0M (+11% YoY) and a net loss of $14.3M ($-0.31/share), wider than the $-0.25 consensus. While product revenue grew 36% and recurring revenue rose 28%, operating expenses surged 18% and cash burn accelerated. The company reaffirmed full-year 2026 guidance of $37-41M revenue and ~20% gross margins, but the widening loss and cash drain overshadow the top-line growth.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $8.0M, up 11% YoY from $7.2M
- Net loss widened to $14.3M ($-0.31/share) vs $11.3M ($-0.26/share) in Q1 2025
- EPS of $-0.31 missed consensus estimate of $-0.25 by 24%
- Product revenue up 36% to $5.6M; recurring revenue up 28% to $5.1M (63% of total)
- Total operating expenses increased 17.9% to $14.2M, with G&A up 30.8%
- Cash, equivalents, and investments fell to $23.2M from $38.6M at year-end 2025
- Reaffirmed FY2026 revenue guidance $37-41M and gross margin ~20%
- Gross margin was 4.6% vs 5.6% in Q1 2025
Financial Impact
EPS miss of 24% ($-0.31 vs $-0.25 consensus) and cash burn of ~$15M in Q1
Risk Factors
- Cash burn rate implies ~4 quarters of runway at current pace
- Operating expenses growing faster than revenue (18% vs 11%)
- Service revenue declined 22% YoY, signaling lumpy validation activity
- Low gross margins (4.6%) limit operating leverage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001380106-26-000067 |
| Document: 0001380106-26-000067-index.html | 0001380106-26-000067 |
| Document: 0001380106-26-000067.txt | 0001380106-26-000067 |
| 8-K Data (Synthetic) | 0001380106-26-000067 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 7, 2026 11w ago | 8-K | $1.73 $1.31 | ▲ +24.28% | ▲ +23.88% | $0.7800 (+54.91%) |
Jul 23, 2026 13w ago | Press Release | $1.99 | awaiting T+20 | — | $0.7800 (−60.80%) |
May 19, 2026 22w ago | 424B5 | $2.01 $1.71 | ▲ +14.93% | ▲ +15.67% | $0.7800 (+61.19%) |
May 13, 2026 23w ago | 8-K | $2.32 $1.76 | ▲ +24.14% | ▲ +23.28% | $0.7800 (+66.38%) |
Apr 8, 2026 28w ago | DEFA14A | $2.12 $2.53 | ▲ +19.34% | ▲ +11.77% | $0.7800 (−63.21%) |
Mar 12, 2026 32w ago | 8-K | $3.43 $2.12 | ▼ −38.10% | ▼ −40.08% | $0.7800 (−77.23%) |
Mar 12, 2026 32w ago | Press Release | $3.43 $2.12 | ▼ −38.10% | ▼ −40.08% | $0.7800 (−77.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers